Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OMNICELL, INC.OMCL · Entity 4666 | Director | June 01, 2026 | June 03, 2026 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OMNICELL, INC.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,100 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 4,845 · Balance 70,100 F1: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares, under the Issuer's equity incentive plan, in consideration of services as a Board Member pursuant to the Issuer's Board of Directors Compensation Plan. Shares shall vest in full on the one-year anniversary of the grant date.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 165,230 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 23,660 · Balance 164,055 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 1,175 · Balance 165,230 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-06 · Exercise / conversion · Disposed 23,660 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 1,174.4921 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date November 16, 2020 · Filed November 18, 2020
Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 58,295 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.72 · Expires 2024-04-11 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 2,974 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F4: These options vested on April 11, 2015. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 2,603 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on May 1, 2016. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 2,788 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on February 17, 2017. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.18 · Expires 2027-03-03 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 2,928 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on March 3, 2018. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 2,984 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on March 2, 2019. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 4,352 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: These options vested on March 2, 2020. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 6,151 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10: These options will vest on March 2, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 9,440 · Balance 0 F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.
F4: These options vested on April 11, 2015.
F5: These options vested on May 1, 2016.
F6: These options vested on February 17, 2017.
F7: These options vested on March 3, 2018.
F8: These options vested on March 2, 2019.
F9: These options vested on March 2, 2020.
F10: These options will vest on March 2, 2021.
F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.
F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 4, 2022 20:08 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 13,996 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-009555 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 00:04 UTC | OMNICELL, INC. OMCL · Entity 4666 | Exercise / conversionStock Option NQ (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0001179110-22-001527 · edgar.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,278 Underlying: Common Stock · 3,000 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Option Exercised and held in the account. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 00:04 UTC | OMNICELL, INC. OMCL · Entity 4666 | Exercise / conversionCommon Stock | 3,000 | $14.87 | $44,610.00 |
DisclosureSEC source: 0001179110-22-001527 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Option Exercised and held in the account. F1 · price: Option Exercised and held in the account. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 00:06 UTC | OMNICELL, INC. OMCL · Entity 4666 | Exercise / conversionStock Option NQ (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0001179110-22-001291 · edgar.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Option Exercised and held in the account. F1 · derivative.underlying_shares: Option Exercised and held in the account. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 00:06 UTC | OMNICELL, INC. OMCL · Entity 4666 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001291 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 18:02 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 120.0574 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-049650 · doc4.xml · derivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334.4826 Underlying: Common Stock · 120.0574 shares Expires not disclosed F1 · derivative.exercise_price: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F1 · derivative.exercise_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F1 · derivative.expiration_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 18:00 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 113.2715 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-037649 · doc4.xml · derivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214.4252 Underlying: Common Stock · 113.2715 shares Expires not disclosed F1 · derivative.exercise_price: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F1 · derivative.exercise_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F1 · derivative.expiration_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:32 UTC | Viatris Inc VTRS · Entity 3277 | GrantDividend Equivalent Units · Derivative | 101.1537 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025585 · doc4.xml · derivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101.1537 Underlying: Common Stock · 101.1537 shares Expires not disclosed F1 · derivative.exercise_price: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F1 · derivative.exercise_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. F1 · derivative.expiration_date: Represents dividend equivalent units ("DEUs") that accrued with respect to restricted stock units ("RSUs") previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. Read SEC document |
| May 25, 2021 Filed May 26, 2021 15:15 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005927 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · shares: Grant of restricted shares in consideration of services as a Board Member. Shares shall vest in full on the date of the Company's 2022 Annual Meeting of Stockholders. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:35 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionRestricted Stock Units · Derivative | 9,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009935 · doc4.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. These RSUs vested in full on March 2, 2021. F2 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. These RSUs vested in full on March 2, 2021. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:35 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 13,996 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009935 · doc4.xml · derivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,996 Underlying: Common Stock · 13,996 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. ("Viatris"). These RSUs will vest on March 2, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. ("Viatris"). These RSUs will vest on March 2, 2022. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:35 UTC | Viatris Inc VTRS · Entity 3277 | Exercise / conversionCommon Stock | 9,440 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009935 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantRestricted Stock Units · Derivative | 9,440 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 9 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,440 Underlying: Common Stock · 9,440 shares Expires not disclosed F12 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination. F12 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination. F13 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. F13 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 6,151 | Not disclosed Strike: $17.48 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 8 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,151 Underlying: Common Stock · 6,151 shares Expires 2030-03-02 F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F11 · derivative.exercise_date: These options will vest on March 2, 2021. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 4,352 | Not disclosed Strike: $27.45 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 7 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Underlying: Common Stock · 4,352 shares Expires 2029-03-01 F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F10 · derivative.exercise_date: These options vested on March 2, 2020. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,984 | Not disclosed Strike: $40.97 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 6 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 Underlying: Common Stock · 2,984 shares Expires 2028-03-02 F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F9 · derivative.exercise_date: These options vested on March 2, 2019. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,928 | Not disclosed Strike: $45.18 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 5 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928 Underlying: Common Stock · 2,928 shares Expires 2027-03-03 F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F8 · derivative.exercise_date: These options vested on March 3, 2018. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,788 | Not disclosed Strike: $46.27 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 4 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,788 Underlying: Common Stock · 2,788 shares Expires 2026-02-17 F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F7 · derivative.exercise_date: These options vested on February 17, 2017. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,603 | Not disclosed Strike: $50.66 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,603 Underlying: Common Stock · 2,603 shares Expires 2025-11-17 F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F6 · derivative.exercise_date: These options vested on May 1, 2016. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,974 | Not disclosed Strike: $45.72 | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · derivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974 Underlying: Common Stock · 2,974 shares Expires 2024-04-11 F4 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F5 · derivative.exercise_date: These options vested on April 11, 2015. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantCommon Stock | 58,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031574 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,313 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F3 · balance_after: Includes 18 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerRestricted Stock Units · Derivative | 9,440 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 9 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,440 shares Expires not disclosed F11 · security: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F11 · price: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F12 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. F12 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 6,151 | Not disclosed Strike: $17.48 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 8 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,151 shares Expires 2030-03-02 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10 · derivative.exercise_date: These options will vest on March 2, 2021. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 4,352 | Not disclosed Strike: $27.45 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 7 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,352 shares Expires 2029-03-01 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9 · derivative.exercise_date: These options vested on March 2, 2020. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,984 | Not disclosed Strike: $40.97 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 6 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,984 shares Expires 2028-03-02 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8 · derivative.exercise_date: These options vested on March 2, 2019. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,928 | Not disclosed Strike: $45.18 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 5 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,928 shares Expires 2027-03-03 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7 · derivative.exercise_date: These options vested on March 3, 2018. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,788 | Not disclosed Strike: $46.27 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 4 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,788 shares Expires 2026-02-17 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6 · derivative.exercise_date: These options vested on February 17, 2017. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,603 | Not disclosed Strike: $50.66 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,603 shares Expires 2025-11-17 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5 · derivative.exercise_date: These options vested on May 1, 2016. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,974 | Not disclosed Strike: $45.72 | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · derivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,974 shares Expires 2024-04-11 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F4 · derivative.exercise_date: These options vested on April 11, 2015. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 19:23 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerOrdinary Shares | 58,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031517 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 18:02 UTC | Mylan II B.V. MYL · Entity 16217 | PurchaseOrdinary Shares | 12,500 | $16.79 | $209,830.00 |
DisclosureSEC source: 0000899243-20-022172 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,295 F1 · price: Represents the weighted average price of the reporting person's acquisition of 12,500 ordinary shares in transactions ranging from $16.78 to $16.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ordinary shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2020 Filed May 27, 2020 15:10 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 2,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006625 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,235 F1 · shares: Grant of restricted shares in consideration of services as a Board Member. Shares shall vest in full on the date of the Company's 2021 Annual Meeting of Stockholders. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:48 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 6,011 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007043 · doc4.xml · derivative · entry 4 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,011 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2020. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2020. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:48 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 9,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007043 · doc4.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,440 Underlying: Ordinary Shares · 9,440 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2021. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2021. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:48 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option-Right to Buy · Derivative | 6,151 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0000899243-20-007043 · doc4.xml · derivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,151 Underlying: Ordinary Shares · 6,151 shares Expires 2030-03-02 F1 · derivative.exercise_date: These options will vest in full on March 2, 2021 and expire on March 2, 2030. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:48 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 6,011 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007043 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2019 Filed May 15, 2019 23:26 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 2,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-006118 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,594 F1 · shares: Grant of restricted shares in consideration of services as a Board Member. Shares shall vest in full on the date of the Company's 2020 Annual Meeting of Stockholders. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:25 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 4,028 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006228 · doc4.xml · derivative · entry 5 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,028 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2019. F4 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2019. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:25 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 1,639 | $27.45 | $44,990.55 |
DisclosureSEC source: 0000899243-19-006228 · doc4.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,784 F1 · shares: Represents withholding of ordinary shares for the U.K. tax liability associated with the settlement of the restricted stock units (RSUs) granted on March 2, 2018. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:25 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 4,028 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006228 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:25 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 6,011 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006228 · doc4.xml · derivative · entry 4 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,011 Underlying: Ordinary Shares · 6,011 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2020. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:25 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option-Right to Buy · Derivative | 4,352 | $0.00 Strike: $27.45 | $0.00 |
DisclosureSEC source: 0000899243-19-006228 · doc4.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Underlying: Ordinary Shares · 4,352 shares Expires 2029-03-01 F2 · derivative.exercise_date: These options will vest in full on March 2, 2020 and expire on March 1, 2029. Read SEC document |
| May 15, 2018 Filed May 16, 2018 17:29 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 2,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006859 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,397 F1 · shares: Grant of restricted shares in consideration of service as a Board member. Shares shall vest in full on the date of the Company's 2019 Annual Meeting of Stockholders. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 20:22 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 3,653 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006545 · doc4.xml · derivative · entry 5 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 3, 2018. F4 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 3, 2018. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 20:22 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 1,525 | $40.97 | $62,479.25 |
DisclosureSEC source: 0000899243-18-006545 · doc4.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,395 F1 · shares: Represents withholding of ordinary shares for the U.K. tax liability associated with the settlement of the restricted stock units (RSUs) granted on March 3, 2017. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 20:22 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 3,653 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006545 · doc4.xml · nonDerivative · entry 1 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 20:22 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 4,028 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006545 · doc4.xml · derivative · entry 4 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,028 Underlying: Ordinary Shares · 4,028 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2019. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2019. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 20:22 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option-Right to Buy · Derivative | 2,984 | $0.00 Strike: $40.97 | $0.00 |
DisclosureSEC source: 0000899243-18-006545 · doc4.xml · derivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 Underlying: Ordinary Shares · 2,984 shares Expires 2028-03-02 F2 · derivative.exercise_date: These options will vest in full on March 2, 2019 and expire on March 2, 2028. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:53 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 182 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007934 · edgar.xml · nonDerivative · entry 3 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,662 F2 · shares: Grant of restricted shares in consideration for services as a member of the Corporate Governance Committee. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| May 23, 2017 Filed May 24, 2017 22:53 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 2,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007934 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,480 F1 · shares: Grant of restricted shares in consideration of service as a Board member. Shares shall vest in full on the date of the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.